secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001558370-23-017991
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track
-------------------------------------------------------------------------

- Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.
- R&D expenses $19.5M GAAP ($16.7M non-GAAP) as Phase 3 palazestrant trial advances.
- OPERA-01 Phase 3 monotherapy trial site activation ongoing, first patient expected Q4 2023.
- New palazestrant combination data with CDK4/6 inhibitors to be presented at SABCS Dec 2023.
- Appointed Scott Garland to board; completed financing up to $180M (equity + credit facility).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/0001558370-23-017991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/olma-20231107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer